Newest
-
China Southern Power Grid's First Overseas Distribution Network Loss Reduction Pilot Project—the South Cairo, Egypt Project—has Successfully Passed Acceptance
-
AIX Incubator Secures U.S. SEC Filing Approval and MSB License, Advancing Its Global Compliance Strategy
-
RWA2035 Global Digital Economy Strategy Summit to Debut in Boao on January 4, 2026
-
Hacken Releases MEXC’s Audit, Confirms Full Asset Backing and Strengthened Transparency Standards
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
2025-02-14
DAAN Biotherapeutics
HaiPress
SEOUL,South Korea,Feb. 13,2025 -- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).
By leveraging DAAN Biotherapeutics' next-generation antibody technology,built upon its exceptional target discovery and antibody development capabilities,LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients.
DAAN Biotherapeutics has successfully established a proprietary pipeline for efficiently developing antibodies targeting overexpressed tumor targets in solid cancers through a strategic partnership with OmniAb.
Byoung Chul Cho,MD,the CEO of DAAN Biotherapeutics,stated,"We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in the ADC field. Beyond ADCs,we also aim to become a global leader in solid tumor-targeting T-cell engagers using our proprietary TACTIC (Tumor Targeting Conditionally Activated T Cell Engager) platform."